Mankind Pharma Acquires Rivotril Brand, Bolsters CNS Therapy Focus
New Delhi, March 18, 2026: Mankind Pharma Limited announced today the acquisition of the Rivotril brand from Roche for the Indian market. The agreement grants Mankind Pharma exclusive rights to manufacture, market, and distribute the product throughout the country.Rivotril is the innovator brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. The acquisition reinforces Mankind Pharma's focus on chronic and central nervous system (CNS) therapies, complementing its existing neuro portfolio.
Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, stated that the acquisition aligns with the company's strategic focus on chronic therapies and presents opportunities for potential line extensions to address evolving patient and physician needs. Mankind Pharma will utilize its extensive distribution network and field force to expand access to Rivotril across India.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is a leading pharmaceutical company in India with a focus on the domestic market. The company operates across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, and respiratory. Mankind Pharma’s distribution network includes a field force of over 17,700 professionals, reaching more than five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities and operates six dedicated R&D facilities with over 730 scientists.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Last edited by a moderator: